As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...
including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs. However, the new study led by Ziyad Al-Aly, a physician-scientist at the Veterans Affairs St ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...